Morgens Waterfall Vintiadis & CO Inc Cellectis S.A. Transaction History

Morgens Waterfall Vintiadis & CO Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$7.81 - $18.82 $132,770 - $319,940	-17,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$14.6 - $20.6 $233,600 - $329,600	-16,000 Reduced 48.48%	17,000 $265,000
Q1 2019 May 15, 2019	BUY	$15.53 - $19.75 $248,480 - $316,000	16,000 Added 94.12%	33,000 $605,000
Q1 2018 May 15, 2018	BUY	$27.78 - $35.19 $472,260 - $598,230	17,000 New	17,000 $536,000
Q4 2017 Feb 14, 2018	SELL	$23.33 - $35.01 $410,607 - $616,176	-17,600 Closed	0 $0

Q3 2017 Nov 14, 2017	BUY	$21.65 - $32.18 $381,040 - $566,368	17,600	17,600 $501,000

9.73M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $101M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Morgens Waterfall Vintiadis & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Morgens Waterfall Vintiadis & CO Inc with notifications on news.